Last reviewed · How we verify
Sorafenib Ramp-Up Regimen
Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis.
Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis. Used for Hepatocellular carcinoma, Renal cell carcinoma, Differentiated thyroid cancer.
At a glance
| Generic name | Sorafenib Ramp-Up Regimen |
|---|---|
| Also known as | Nexavar (Bay43-9006) |
| Sponsor | University of Florida |
| Drug class | Multi-kinase inhibitor |
| Target | BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Sorafenib inhibits multiple receptor tyrosine kinases including BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, and c-KIT. By blocking these pathways, it suppresses both tumor cell growth and the formation of new blood vessels that tumors depend on for survival. The ramp-up regimen refers to a dose escalation schedule designed to improve tolerability by gradually increasing from a lower starting dose to the therapeutic dose.
Approved indications
- Hepatocellular carcinoma
- Renal cell carcinoma
- Differentiated thyroid cancer
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Rash
- Fatigue
- Hypertension
- Nausea
- Anorexia
Key clinical trials
- FLT3-ITD Targeted Therapy in Fit AML Patients (PHASE2, PHASE3)
- Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorafenib Ramp-Up Regimen CI brief — competitive landscape report
- Sorafenib Ramp-Up Regimen updates RSS · CI watch RSS
- University of Florida portfolio CI